Q-omics provides the consensus-scored EVC profile across patient tissues and cancer cell-line models. EVC expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EVC is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, EVC RNA expression shows 19,634 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where EVC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EVC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EVC survival associations across molecular data types. EVC RNA expression shows survival associations in the most cancer types (28), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EVC RNA expression–survival associations across cancer types. High EVC expression shows unfavorable associations in BLCA, MESO, LGG and UVM, but favorable associations in KIRC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EVC RNA expression.
This table summarizes EVC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for EVC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EVC shows lower tumor expression in KIRC, KICH, BLCA, THCA and UCEC and higher tumor expression in HNSC. The HNSC box plot shows higher EVC RNA expression in tumor versus normal tissue (log2 FC = +1.106, t-test p < 0.001).
This table shows molecular features associated with EVC in patient tissues and cancer cell lines. In patient samples, EVC shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, EVC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
